孟鲁司特对哮喘患者NF-κB、IL-10及气道反应的作用

目的：观察孟鲁司特对哮喘患者外周血NF—κB活性、IL-10水平及气道反应性的作用。方法：对40例哮喘患者（治疗组）在常规治疗的基础上加用孟鲁司特治疗3个月。观察治疗前后外周血NF—κB活性，血浆IL-10、IgE的水平和嗜酸性粒细胞（EOS）计数的变化，并进行气道反应性测定。并以30例同期入选的健康体检者作对照（对照组）。结果：治疗组患者治疗前外周血NF—κB活性、血浆IgE水平和EOS细胞数高于对照组，血浆IL-10水平低于对照组，治疗后外周血NF—κB活性、血浆IgE水平和EOS细胞数降低，IL—10水平上升。同时气道对组胺的反应阈值Dmin提高，对组胺的反应性Rrsc降低。结论：孟鲁司特治疗哮喘的作用机制可能是通过上调IL-10水平，降低NF—κB活性，从而抑制EOS聚集，达到治疗哮喘的目的。

Effect of Montelukast on NF-KB Activity,IL-10 Level and Airway Response of Patients with Asthma

Objective： To observe the effect of Montelukast on NF-κB activity, IL-10 levels in the peripheral blood and airway response of patients with asthma. Method： Forty cases of asthma patients （treatment group） were undergone the conventional treatment together with montelukast for 3 months. NF-κB activity in peripheral blood, plasma IL-10, IgE level and eosinophils （EOS） count changes were observed before and after treatment, and airway reaction was determined. Thirty cases of healthy people were selected as control group. Result： NF-κB activity in peripheral blood, plasma IgE level and EOS cell count were higher in the treatment group than those of the control group before treatment, while plasma IL-10 levels were lower than that of the control group. NF-κB activity in pe- ripheral blood, plasma IgE level and EOS cell count is decrease, while IL-10 levels are increase after treatment. At the same time, the threshold of airway response to histamine Dmin was increase and the response to histamine Rrsc was lowered. Conclusion： NF-κB activity in peripheral blood is increase, plasma levels of IL-10 are decrease in the patients with Asthma. the mechanism of montelukast in the treatment of asthma may be through the increase of IL-10 level and the decrease of the NF-κB activity, it may be inhibit the aggregation of EOS to reach the aim of treating asthma.